We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 4 for:    Emtricitabine/Tenofovir Alafenamide | Recruiting Studies | Phase 3 | Industry
Previous Study | Return to List | Next Study

Switching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in HIV-1 Infected Adults Who Are Virologically Suppressed

This study is currently recruiting participants.
Verified December 2017 by Gilead Sciences
Sponsor:
ClinicalTrials.gov Identifier:
NCT03110380
First Posted: April 12, 2017
Last Update Posted: December 8, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
Gilead Sciences
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: March 2021
  Estimated Primary Completion Date: February 2019 (Final data collection date for primary outcome measure)